本報(bào)道最初發(fā)表于Endpoints News。請點(diǎn)擊這里查看原文
One of the most closely watched obesity assets in the clinic, Lilly’s triple-G agonist retatrutide, caused patients with obesity and knee osteoarthritis to lose an average of 23.7% of their body weight at around 16 months in a late-stage trial.
在一項(xiàng)后期臨床試驗(yàn)中，作為臨床上最受關(guān)注的減重資產(chǎn)之一，禮來的三靶點(diǎn)激動(dòng)劑 retatrutide 使患有肥胖和膝骨關(guān)節(jié)炎的患者在約16個(gè)月時(shí)平均減重23.7%。
您已閱讀6%（357字），剩余94%（5462字）包含更多重要信息，訂閱以繼續(xù)探索完整內(nèi)容，并享受更多專屬服務(wù)。